Wada, Takashi
Inagaki, Masaya
Yoshinari, Toru
Terata, Ryuji
Totsuka, Naoko
Gotou, Miki
Hashimoto, Gaia
Funding for this research was provided by:
Mitsubishi Tanabe Pharma Corporation.
Article History
Received: 26 March 2020
Accepted: 26 August 2020
First Online: 24 September 2020
Compliance with ethical standards
:
: Takashi Wada has received advisory fees and lecture fees from Mitsubishi Tanabe Pharma Corporation. Masaya Inagaki, Toru Yoshinari, Ryuji Terata, Naoko Totsuka, Miki Gotou and Gaia Hashimoto are employees of Mitsubishi Tanabe Pharma Corporation.
: These studies were conducted in accordance with the ethical principles of the Helsinki Declaration, the Pharmaceutical and Medical Device Act and good clinical practice, and the study was approved by the Institutional Review Board of each participating study center. All study patients provided informed consent prior to the start of treatment. The studies were registered at ClincialTrials.gov under the identifier numbers NCT02517320 (dose–response study) and NCT02676401 (extension study).